See the DrugPatentWatch profile for sogroya
What patent covers Sogroya (somapacitan), and who owns it?
Sogroya is the brand name for somapacitan, a long-acting human growth hormone (GH) analog. The specific patents that protect Sogroya depend on the jurisdiction and the exact claim set (composition of matter, formulation, dosing regimen, or method-of-use), and the owner(s) can include the original developer and later assignees.
However, I don’t have any provided source text here that identifies the exact patent number(s) or owner for “Sogroya.” If you share a link, patent number, or the country (e.g., US, EP, UK, JP), I can summarize what that patent covers and what it would protect.
When does Sogroya’s patent expire?
Patent expiry for Sogroya varies by country because it depends on:
- the filing date of the relevant patents,
- whether the patent terms are extended (e.g., regulatory extensions),
- and whether there are multiple layered patents (drug substance + formulations + use).
Without the specific patent(s) in question, I can’t give a reliable expiry date.
Are there challenges to Sogroya’s patents (biosimilar or generic risk)?
For biologics/biologic-like products such as long-acting GHs, the competitive threat often comes from:
- manufacturers seeking market entry once exclusivity/patents allow,
- challenges through patent litigation or regulatory pathways.
To answer this accurately for Sogroya, I’d need the jurisdiction and the specific patent(s) being asserted.
What does “Sogroya” patent protection usually include?
Long-acting GH products typically have patent coverage spanning:
- the drug molecule (composition claims),
- linkers/chemical variants or conjugation approaches,
- manufacturing/formulation (including delivery or release characteristics),
- and sometimes method-of-use and dosing regimens.
If you provide the patent number(s) you’re looking at, I can map those claims to what they likely cover.
What country are you asking about?
Patent details and expiry dates differ a lot by country. Tell me one of these and I’ll tailor the answer:
- United States
- European Union / EP validation
- United Kingdom
- Canada
- Japan
- Other
Send me one of these and I’ll pull the exact answer
Paste any of the following:
- the patent number (e.g., “US xxxx…“ or “EP …”),
- a website link to the patent listing,
- the application/publication number,
- the country/jurisdiction,
- or the text you’re working from.
Sources: None provided.